The Alzheimer's Research Podcast

Alzheimer's Therapeutic Research Institute

Brought to you by the Alzheimer’s Therapeutic Research Institute (ATRI), The Alzheimer’s Research Podcast offers an inside look at the science, stories, and people driving progress in the fight against Alzheimer’s disease. Through engaging conversations with researchers, study participants, and leading experts, we explore the latest discoveries, ongoing clinical trials, and the real-world impact of groundbreaking studies.

Episodes

  1. 07/01/2025

    The Earliest Clues: How Genetic Populations Illuminate the Path to Alzheimer’s Prevention

    Whether he’s leading a clinical trial or advising film and television writers on accurate portrayals of Alzheimer’s, Dr. Michael Rafii knows that clear, accessible communication matters. In this episode, Dr. Rafii joins the podcast to discuss his work as Medical Director of ATRI and Director of the Medical Safety Unit of ACTC. He shares a fascinating overview of his clinical research around developing new treatments for a genetic form of Alzheimer’s in people with Down syndrome and explains how Alzheimer’s research has evolved throughout his career. Dr. Rafii also discusses his approach to communicating complex medical topics in a way that’s clear and easy to understand. Episode Recap: In this episode, we’re talking with ATRI Medical Director Dr. Michael Rafii (0:41)Can you tell us about your role at ATRI and the work you’re doing with Alzheimer’s clinical trials? (1:40) How did you get involved with Alzheimer’s research, and how has it evolved? (4:29)Can you tell us about your work at the intersection of Alzheimer’s and Down syndrome? (11:15)How do genetics connect to Alzheimer’s risk? (20:13)What are some of the barriers to research for people with Down syndrome? (22:52)How are you working to educate the next generation of researchers? (28:00)What are your hopes for the future of Alzheimer’s research? (34:25)Can you tell us more about what the current clinical studies are testing? (36:33)Why is clear, easy-to-understand communication so important in this space? (39:20)Learn more about ATRI

    46 min
  2. 06/02/2025

    The Role of Regulatory Affairs in Advancing Alzheimer’s Research with Elizabeth Shaffer

    Regulatory affairs is one of the key mechanisms that keeps clinical trials moving forward — ensuring participant consent, overseeing the review process, and helping trials occur faster. In this episode, Elizabeth Shaffer joins the podcast to discuss her work as Regulatory Affairs Manager for the Alzheimer’s Therapeutic Research Institute (ATRI) and the Alzheimer’s Clinical Trials Consortium (ACTC). She shares an overview of the consent process for participants, explains what Institutional Review Boards (IRB) are, and how they oversee research.  She discusses some key advancements in the regulatory process for Alzheimer’s clinical trials throughout her career. Elizabeth also reflects on ATRI’s progress and shares some of her hopes for the future of Alzheimer’s research.  Episode Recap: In this episode, we’re talking with ATRI’s Regulatory Affairs Manager, Elizabeth Shaffer (0:40)How did you get involved with regulatory affairs? (2:27)What is regulatory, and how has it evolved since you started working in this field? (5:46)What role does the IRB play in clinical research? (8:37)How do you make sure you’re communicating clearly to trial participants? (9:35)What are you most excited about in your work today? (13:10)How does your work make research faster and more accessible? (17:09)What does the consent process look like for participants throughout a trial? (18:36)What keeps you motivated to do this work, and what are you most proud of? (24:49) What is your hope for the future of ATRI? (30:09)Learn more about ATRI Connect with Elizabeth Shaffer

    35 min

About

Brought to you by the Alzheimer’s Therapeutic Research Institute (ATRI), The Alzheimer’s Research Podcast offers an inside look at the science, stories, and people driving progress in the fight against Alzheimer’s disease. Through engaging conversations with researchers, study participants, and leading experts, we explore the latest discoveries, ongoing clinical trials, and the real-world impact of groundbreaking studies.